Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-30813 +/- Tislelizumab in Advanced Solid Tumors
NCT05904496Phase 1Terminated
- Sponsor
- BeiGene
- Start
- Jul 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of BGB-30813 in solid tumor (advanced stage) (3 arms), sponsored by BeiGene. Primary endpoints: Adverse Events, Maximum Tolerated Dose up to 6 months and 2 more. Started Jul 2023; status: terminated.
02
Drugs
BGB-30813
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05904496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904496.